{
    "clinical_study": {
        "@rank": "151",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 13, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04330144"
        },
        "id_info": {
            "org_study_id": "3-2020-0036",
            "nct_id": "NCT04330144"
        },
        "brief_title": "Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)",
        "official_title": "A Study of Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)",
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gangnam Severance Hospital",
                "agency_class": "Other"
            }
        },
        "source": "Gangnam Severance Hospital",
        "oversight_info": {
            "has_dmc": "Yes",
            "is_fda_regulated_drug": "No",
            "is_fda_regulated_device": "No",
            "is_us_export": "No"
        },
        "brief_summary": {
            "textblock": "There is no known definite treatment after exposure to SARS-CoV-2, but the some animal and\n      clinical trials confirmed the efficacy of hydroxychloroquine (HCQ) or chloroquine against\n      SARS-CoV-2. Thus, in this study, we aim to evaluate the efficacy and safety of\n      hydroxychloroquine as post exposure prophylaxis for SARS-CoV-2.\n\n        -  Primary end point: comparison the rate of COVID-19 between PEP with HCQ and control\n           group.\n\n        -  Secondary end point: Comparison of the rate of COVID-19 according to the contact level\n           (time, place, degree of wearing personal protective equipment).\n\n        -  Safety comparison: Safety verification by identifying major side effects in the HCQ\n           group.\""
        },
        "overall_status": "Not yet recruiting",
        "start_date": {
            "@type": "Anticipated",
            "#text": "April 1, 2020"
        },
        "completion_date": {
            "@type": "Anticipated",
            "#text": "March 30, 2022"
        },
        "primary_completion_date": {
            "@type": "Anticipated",
            "#text": "March 30, 2021"
        },
        "phase": "Phase 3",
        "study_type": "Interventional",
        "has_expanded_access": "No",
        "study_design_info": {
            "allocation": "Randomized",
            "intervention_model": "Parallel Assignment",
            "primary_purpose": "Prevention",
            "masking": "Single (Outcomes Assessor)"
        },
        "primary_outcome": {
            "measure": "The rate of COVID-19",
            "time_frame": "PCR test of COVID-19 at 14 days after the contact from confirmed case",
            "description": "After postexposure prophylaxis, the rate of COVID-19 conversion between two groups"
        },
        "number_of_arms": "2",
        "enrollment": {
            "@type": "Anticipated",
            "#text": "2486"
        },
        "condition": "Contact Person From COVID-19 Confirmed Patient",
        "arm_group": [
            {
                "arm_group_label": "administration of hydroxychloroquine as PEP",
                "arm_group_type": "Experimental"
            },
            {
                "arm_group_label": "control with no PEP",
                "arm_group_type": "Active Comparator"
            }
        ],
        "intervention": [
            {
                "intervention_type": "Drug",
                "intervention_name": "Hydroxychloroquine as post exposure prophylaxis",
                "description": "1day: Hydroxychloroquine 800mg Qd po 2-5dy: Hydroxychloroquine 400mg Qd po",
                "arm_group_label": "administration of hydroxychloroquine as PEP"
            },
            {
                "intervention_type": "Other",
                "intervention_name": "Others(No intervention)",
                "description": "No treatment. Close monitoring and quarantine.",
                "arm_group_label": "control with no PEP"
            }
        ],
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A contact person from confirmed case of SARS-CoV-2 infection\n\n          -  Medical staff exposed from confirmed case of SARS-CoV-2 infection in hospitals\n\n          -  Persons exposed to SARS-CoV-2 in COVID-19 outbreak situation with certain workplaces,\n             religious groups, and military, etc.\n\n               -  Subjects of study include both symptomatic and asymptomatic contacts.\n\n        Exclusion Criteria:\n\n          -  Hypersensitivity to Chloroquine or Hydroxychloroquine\n\n          -  Those who are contraindicated in Hydroxychloroquine administration according to the\n             permission requirements such as pregnant women, nursing mothers, visual disorders,\n             macular disease, and porphyria, etc.\n\n          -  Human immunodeficiency virus (HIV) infected person\n\n          -  Patients with autoimmune disease (Systemic lupus erythematosus, Mixed connective\n             tissue disease)\n\n          -  Patients with autoimmune rheumatoid inflammatory disease (AIIRD; Autoimmune\n             inflammatory rheumatic diseases - Ankylosing spondylitis, Rheumatic arthritis,\n             Psoriatic arthritis)\n\n          -  Arrhythmia, liver cirrhosis of Child Pugh C, chronic renal failure with eGFR\u226430mL /\n             min / 1.73m2\n\n          -  A person who is positive in the COVID-19 screening PCR test before starting PEP"
            },
            "gender": "All",
            "minimum_age": "18 Years",
            "maximum_age": "99 Years",
            "healthy_volunteers": "Accepts Healthy Volunteers"
        },
        "overall_official": {
            "last_name": "Yong Goo Song, Professor",
            "role": "Principal Investigator",
            "affiliation": "Gangnam Severance Hospital"
        },
        "overall_contact": {
            "last_name": "Yong Goo Song, Professor",
            "phone": "82-2-2019-3310",
            "phone_ext": "3310",
            "email": "imfell@yuhs.ac"
        },
        "verification_date": "March 2020",
        "study_first_submitted": "March 30, 2020",
        "study_first_submitted_qc": "March 31, 2020",
        "study_first_posted": {
            "@type": "Actual",
            "#text": "April 1, 2020"
        },
        "last_update_submitted": "March 31, 2020",
        "last_update_submitted_qc": "March 31, 2020",
        "last_update_posted": {
            "@type": "Actual",
            "#text": "April 1, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Principal Investigator",
            "investigator_affiliation": "Gangnam Severance Hospital",
            "investigator_full_name": "Young Goo Song",
            "investigator_title": "Professor, Department of Internal Medicine,"
        },
        "keyword": [
            "Postexposure prophylaxis",
            "hydroxychloroquine",
            "SARS-CoV-2",
            "COVID-19"
        ],
        "intervention_browse": {
            "mesh_term": "Hydroxychloroquine"
        }
    }
}